Table 1 Clinical trials targeting the ECM
Target | Drug | Combination | Condition | Phase | Status | Trial number |
|---|---|---|---|---|---|---|
LOXL2 | Simtuzumab | Gemcitabine | Pancreatic Cancer | II | Completed | NCT01472198 |
| Â | Â | FOLFIRI | Colorectal Cancer | II | Terminated | NCT01479465 |
| Â | PAT-1251 | No | Healthy | I | Completed | NCT02852551 |
LOX | PXS-5382A | No | Healthy | I | Completed | NCT04183517 |
Hyaluronic acid | PEGPH20 | Pembrolizumab | Pancreatic Cancer/Pancreatic Ductal Adenocarcinoma | II | Recruiting | NCT03634332 |
| Â | Â | Gemcitabine | Pancreatic Adenocarcinoma Non-resectable | II | Terminated | NCT02910882 |
| Â | Â | Pembrolizumab | NSCLC/Gastric Cancer | I | Completed | NCT02563548 |
| Â | Â | Cetuximab | Pancreatic Cancer | Not Applicable | Completed | NCT02241187 |
| Â | Â | Avelumab | Pancreatic Ductal Adenocarcinoma/Pancreatic Cancer | I | Terminated | NCT03481920 |
| Â | Â | Docetaxel | Non-small Cell Lung Cancer | I | Terminated | NCT02346370 |
| Â | Â | Eribulin mesylate | Metastatic Breast Cancer | I/II | Terminated | NCT02753595 |
| Â | Â | No | Solid Tumor | I | Completed | NCT01170897 |
| Â | Â | Gemcitabine | Pancreatic Cancer | I/II | Completed | NCT01453153 |
| Â | Â | FOLFIRINOX | Metastatic Pancreatic Adenocarcinoma | I/II | not recruiting | NCT01959139 |
| Â | Â | No | Solid Tumor | I | Completed | NCT00834704 |
| Â | Â | CIS/GEM/Atezolizumab | Cholangiocarcinoma | I | Terminated | NCT03267940 |
| Â | Â | Nabpaclitaxel/Gemcitabine | Metastatic Pancreatic Cancer | II | Completed | NCT01839487 |
| Â | Â | Atezolizumab | Pancreatic Ductal Adenocarcinoma | II | Terminated | NCT03979066 |
| Â | Â | Gemcitabine/Nab-paclitaxel | Adenocarcinoma | II | Terminated | NCT02487277 |
| Â | Â | NabPaclitaxel/Gemcitabine | Pancreatic Ductal Carcinoma | III | Terminated | NCT02715804 |
CTGF | Pamrevlumab | Gemcitabine combined with nab-paclitaxel | Metastatic Pancreatic Cancer | III | Recruiting | NCT04229004 |
| Â | Pamrevlumab | Pamrevlumab,Gemcitabine, Nab-paclitaxel, or Pamrevlumab, FOLFIRINOX | Pancreatic Cancer Non-resectable | III | Active, not recruiting | NCT03941093 |
Integrin | Cilengitide | Temozolomide,radiotherapy | Glioblastoma | III | Â | NCT00689221 |
| Â | ATN-161 | Carboplatin | Malignant glioma | I/II | Completed | NCT04177108 |
| Â | MEDI-522 | Dacarbazine | Metastatic melanoma | II | Completed | NCT00066196 |
TGF-β | Fresolimumab | Radiation Therapy | Metastatic Breast Cancer | II | Completed | NCT01401062 |
| Â | Â | Radiation Therapy | Non-Small Cell Lung Carcinoma | I/II | Completed | NCT02581787 |
FAK | Defactinib/PF-04554878 | No | Malignant Pleural Mesothelioma | II | Terminated | NCT01870609 |
| Â | Â | No | Non-Small Cell Lung Cancer | II | Completed | NCT01951690 |
| Â | Â | No | Solid Tumor | I | Completed | NCT00787033 |
| Â | Â | No | Non-Hematologic Malignancies | I | Completed | NCT01943292 |
| Â | Â | No | Advanced tumor | II | Active, not recruiting | NCT04439331 |
| Â | Â | VS-6766 | Ovarian Cancer | II | Recruiting | NCT04625270 |
| Â | Â | Paclitaxel | Ovarian Cancer | I | Completed | NCT01778803 |
| Â | Â | VS-6766 | Lung cancer/ ovarian cancer/ endometrioid carcinoma / pancreatic cancer | I | Recruiting | NCT03875820 |
| Â | Â | VS-6766 | Non-Small Cell Lung Cancer | II | Recruiting | NCT04620330 |
| Â | Â | Pembrolizumab, Gemcitabine | Solid tumors / pancreatic cancer | I | Completed | NCT02546531 |
| Â | Â | Paclitaxel, carboplatin | Ovarian cancer | I/II | Recruiting | NCT03287271 |
Hedgehog | Sonidegib (LDE225) | Docetaxel | Triple Negative (TN) Advanced Breast Cance | I | Completed | NCT02027376 |
| Â | Â | No | Basal Cell Carcinoma | II | Completed | NCT01327053 |
| Â | Â | Gemcitabine | Pancreatic Cancer | I | Completed | NCT01487785 |
| Â | Â | No | Hepatocellular Carcinoma | I | Completed | NCT02151864 |
| Â | Â | Etoposide or Cisplatin | Small Cell Lung Cancer | I | Completed | NCT01579929 |
| Â | Â | Pembrolizumab | Advanced Solid Tumors | I | Recruiting | NCT04007744 |
| Â | Â | Fluorouracil, Leucovorin, Oxaliplatin, Irinotecan | Pancreatic Cancer | I | Completed | NCT01485744 |
| Â | Vismodegib | No | Basal Cell Carcinoma | II | Completed | NCT03035188 |
| Â | Â | Modified FOLFOX or FOLFIRI | Metastatic Colorectal Cancer | II | Completed | NCT00636610 |
| Â | Â | Gemcitabine Hydrochloride | Pancreatic Cancer | II | Completed | NCT01195415 |
| Â | Â | Gemcitabine or nab-Paclitaxel | Pancreatic Cancer | II | Completed | NCT01088815 |